Alaunos Therapeutics
The Company has identified a lead compound for continued preclinical evaluation. The Company completed two non-GLP (Good Laboratory Practice) pharmacology studies, establishing proof-of-concept in the diet induced obesity (DIO) mouse model. Observations from the studies conducted were encouraging and consistent with statistically significant dose-related reductions in body weight.
Basic Information
- Category: public company
- Founded: 2010
- Website: https://alaunos.com/
Documented Facts
- Email: info@alaunos.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: DE (No linked source recorded for this statement.)
- Stock ticker: TCRT (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Alaunos Therapeutics — Official Site (official)
- Alaunos Therapeutics on linkedin (social)
- Alaunos Therapeutics, Inc. — SEC EDGAR (reference)
Citation Guidance
Explore public company profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Alaunos Therapeutics.
- Canonical profile: https://brandsource.ai/brands/alaunos-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/alaunos-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/alaunos-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
The Company has identified a lead compound for continued preclinical evaluation. The Company completed two non-GLP (Good Laboratory Practice) pharmacology studies, establishing proof-of-concept in the diet induced obesity (DIO) mouse model. Observations from the studies conducted were encouraging and consistent with statistically significant dose-related reductions in body weight.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.